Zio Patch Review: Accuracy, Cost, and Who Actually Needs One

Fourteen days, one wire-free sensor, and an algorithm trained on tens of thousands of patients: why a bandage-sized patch displaced the Holter monitor, and what it still cannot tell you about your heart.

In the late 1940s, a physicist in Helena, Montana, set out to do something that sounds ordinary now and was close to absurd then: record the electrical life of a human heart while its owner went about the day. Norman Holter’s early apparatus weighed roughly 40 kilograms, close to 90 pounds. To be monitored was to carry a small radio station on your back.

Holter spent decades shrinking it. The result, a recorder clipped to the belt with wires running to electrodes across the chest, became one of cardiology’s most familiar tools and still carries his name. It also carried a flaw that no amount of miniaturization could fix. Hearts do not misbehave on schedule. A flutter that arrives every nine days will almost never land inside a 24-hour recording, and the patient walks out with a normal report and the same unexplained symptom.

The Zio patch is the answer that won. Made by San Francisco based iRhythm Technologies, it is a single adhesive strip with no wires and no belt box, worn on the upper left chest for up to 14 days. In that time a heart beating 70 times a minute fires about 1.4 million times, and the patch records every one. Then it goes back in the mail, software built on deep learning reads the recording, and a report lands with the clinician who ordered it. The idea is simple: if the problem is rare, look longer. The execution, and the evidence behind it, is more interesting than the idea.

What Is the Zio Patch?

The Zio patch is a prescription, single-lead electrocardiogram (ECG) monitor made by iRhythm Technologies that records heart rhythm continuously for up to 14 days. You wear it on the chest, mail it back, and your clinician receives an analyzed report. It is a diagnostic test, not a consumer wearable, and it is built to answer one question: what is my heart doing when I feel that?

Zio is a family rather than a single device. The Zio XT is the original 14-day patch and the one behind most of the published research. The Zio monitor is the redesigned current generation, built around a more flexible body and a stronger adhesive meant to stay put for the full wear period; the FDA cleared a 510(k) for it (K243650) in August 2025. Both store data on the patch and report after the wear period ends. The Zio AT is different in kind: it transmits during wear, which lets iRhythm provide mobile cardiac telemetry for patients who need closer watching. When a cardiologist says “Zio,” they usually mean the 14-day record-and-review patch, and that is the focus of this review.

Behind the patch sits the part you never see. iRhythm’s analysis platform, which the company calls ZEUS (Zio ECG Utilization Software), processes each returned recording before a report goes to the ordering clinician. You do not get an app full of graphs. You get an answer, delivered through the person who asked the question.

How Does the Zio Heart Monitor Work?

Every heartbeat begins as an electrical wave that sweeps from the top of the heart to the bottom. The Zio patch measures the voltage that wave creates between two electrodes on your chest, producing one continuous ECG trace for up to two weeks. Software then classifies the rhythm beat by beat, and the findings are compiled into a report for your clinician.

Picture the heart as a two-story house with a single fuse box. The spark starts in the sinoatrial node, a cluster of cells in the upper right chamber, and ripples across both upper chambers, the atria, which squeeze blood down into the ventricles. The signal then pauses for a fraction of a second at the atrioventricular node, a deliberate delay that lets the ventricles fill, before racing down specialized wiring and firing the ventricles in one powerful, coordinated contraction. On an ECG that sequence draws a familiar signature: a small P wave for the atria, a tall spike called the QRS complex for the ventricles, and a T wave as they reset.

In atrial fibrillation, the most common sustained arrhythmia, that orderly sequence collapses upstairs. The atria stop contracting and start quivering, hundreds of chaotic impulses a minute, and the P wave disappears into a ragged baseline. The atrioventricular node lets some of those impulses through and blocks others at random, so the ventricles beat in a pattern cardiologists call “irregularly irregular.” That signature is legible on a single lead, which is why one lead is enough for most rhythm questions even though it is far from enough for every heart question.

The patient’s part is minimal. You wear the patch through sleep, work, and ordinary exercise. When you feel a flutter or a skipped beat, you press the button on the device and note what you felt, so the report can line up your symptom against what your heart was actually doing at that second. That symptom correlation is often the most useful sentence in the whole report: either the palpitation matched a real arrhythmia, or it happened during a perfectly normal rhythm, which is its own kind of answer.

The reading is where Zio’s scale turns into an advantage. In 2019, a Stanford team working with iRhythm scientists trained a deep neural network on 91,232 single-lead ECG records from 53,549 patients who had worn the company’s monitor, then tested it against a consensus panel of board-certified cardiologists. The network’s average F1 score, a measure that balances catching true events against raising false alarms, was 0.837; the average individual cardiologist scored 0.780 (Nature Medicine, 2019). That is a study, not a promise about any single report, and iRhythm co-authored it. But it explains why a two-week recording, which would be punishing for a human to read beat by beat, is practical at all.

The same data is now being pushed toward prediction. Researchers at Scripps and iRhythm trained a model on 459,889 patch recordings to estimate, from a single day of normal rhythm, whether atrial fibrillation was likely to appear within two weeks. It reached an area under the curve of 0.80, against 0.67 for age and other demographics alone (npj Digital Medicine, 2023). It is research, not a feature on your report today, but it hints at where long recordings are heading: from “what happened” toward “what is about to.”

How Accurate Is the Zio Patch? What the Research Shows

For catching arrhythmias that come and go, the Zio patch outperforms a 24-hour Holter in head-to-head and real-world studies, mainly because it records up to 14 times longer. The evidence is strongest for diagnostic yield and fewer repeat tests. It is weakest for the bigger claim that screening people without symptoms prevents strokes.

Head to head with a Holter. At the Scripps Translational Science Institute, 146 patients referred for arrhythmia evaluation wore a conventional 24-hour Holter and a 14-day Zio patch at the same time. Over each device’s full wear time, the patch detected 96 arrhythmia events and the Holter detected 61 (American Journal of Medicine, 2014). This is partly a comparison of time, and that is exactly the point. Duration is the feature.

Finding hidden atrial fibrillation. The mSToPS trial randomized 2,659 members of a national health plan who were at elevated risk of atrial fibrillation to wear a self-applied ECG patch, for up to four weeks, either right away or four months later. By four months, new atrial fibrillation had been diagnosed in 3.9 percent of the immediate group and 0.9 percent of the delayed group (JAMA, 2018). At one year, monitored people were more likely to start an anticoagulant and to see a cardiologist, with no difference in atrial fibrillation related emergency visits or hospitalizations. Several authors worked for Janssen, which sells an anticoagulant. That does not make the result wrong. It is simply worth knowing who was in the room.

The real world, at Medicare scale. The largest comparison of monitoring strategies, known as CAMELOT, used the full Medicare claims database: 287,789 patients monitored for the first time in 2017 and 2018. Compared with Holter monitors, event monitors, mobile telemetry, and other manufacturers’ long-term patches, the Zio XT had the highest adjusted odds of producing a new arrhythmia diagnosis and the lowest adjusted odds of the patient needing yet another monitor (American Heart Journal, 2024). As a category, long-term continuous patches were associated with the lowest added healthcare spending over a year: about $10,159 per patient, versus $10,755 for Holter, $11,462 for event monitors, and $12,532 for mobile telemetry. The design is retrospective, which means it can show association rather than cause, and three of the eight authors were iRhythm employees.

Younger, privately insured patients. iRhythm’s follow-up analysis, called AVALON, looked at 428,707 commercially insured patients with a mean age of 46. The company reported repeat testing within 180 days of 3.1 percent with Zio, compared with 6.2 percent for Holter and 5.6 percent for other long-term monitors. These results were presented at the Heart Rhythm Society meeting in 2025 and announced by the company; treat them as supportive until the full peer-reviewed analysis is in hand.

The hardest test: screening. GUARD-AF asked whether giving a 14-day patch to adults aged 70 and older at routine primary care visits would prevent strokes. The pandemic throttled enrollment, and the trial stopped at 11,931 participants rather than the planned 52,000 (American Heart Journal, 2022). In the screening arm, 4.4 percent of the 5,684 people with analyzable patches had atrial fibrillation, and most of it was a whisper: the median person with intermittent atrial fibrillation spent 0.46 percent of the two weeks in it, about 75 minutes, though a quarter of them logged several hours (JACC: Clinical Electrophysiology, 2025). The primary results, published in the Journal of the American College of Cardiology in 2024, did not show that screening reduced strokes, and the shrunken trial was too small to settle the question either way. Its authors included employees of Bristol Myers Squibb and Pfizer, which jointly sell the anticoagulant apixaban, and of iRhythm.

Read together, the studies say three things clearly. Looking longer finds more intermittent arrhythmias. Zio has the deepest evidence base of any long-term patch, including real-world data suggesting fewer second tests. And finding more atrial fibrillation in people who feel fine is not yet the same thing as preventing strokes. If you want a framework for weighing claims like these, our explainer on what “clinically validated” actually means is a useful companion.

What the Zio Patch Gets Right

The Zio patch gets the most important thing right: it matches the length of the test to the behavior of the disease. Its other strengths, comfort, adherence, and analysis at scale, all serve that one idea.

Duration matched to biology. Intermittent arrhythmias are a probability problem. If an episode arrives once a week, a 24-hour recording has roughly a one in seven chance of catching it; a two-week recording should catch it about twice. Every other advantage of the patch flows from that arithmetic.

It disappears into a life. With no wires and no box, people actually wear it. In GUARD-AF, 96 percent of participants in the screening arm returned a patch with analyzable results, a striking figure for a test mailed to and from people in their seventies and eighties. A monitor that comes back half empty is not a 14-day test, and adherence is where many monitors quietly fail.

Fewer second tests. The repeat-testing data from CAMELOT and AVALON matter more than they sound. Every inconclusive monitor means another appointment, another device, and another few weeks of not knowing. For a patient, the most valuable feature of a test is often that it was the last one.

Reading at scale. Two weeks of continuous ECG is far too much for a person to review heartbeat by heartbeat. Pairing a large training dataset with deep learning makes the long recording usable, and the 2019 Nature Medicine work suggests the machine side of that pairing performs at a high level.

A real answer to “was that my heart?” The symptom button turns a vague complaint into a timestamped data point. A palpitation that lines up with normal rhythm can end months of worry; one that lines up with an arrhythmia gives your clinician something specific to treat.

Where the Zio Patch Falls Short

The Zio patch tells you what happened, not what is happening; it reads one lead, not twelve; and its fortnight is still a window that rare events can slip past. Long monitoring also finds borderline findings that can lead to treatment decisions with real tradeoffs.

It is not live. The standard Zio patch records and reports after the fact. If a dangerous rhythm occurs on day three, no one sees it until the patch is returned and read. For patients whose clinicians need real-time alerts, mobile cardiac telemetry, such as the BioTelemetry MCOT patch or iRhythm’s own Zio AT, is the right tool.

One lead is a narrow window. A single lead is excellent for rhythm and poor at nearly everything else. It cannot diagnose a heart attack, pinpoint where an abnormal beat originates with the precision of a 12-lead ECG, or assess the heart’s structure or valves. A normal Zio report says your rhythm behaved for two weeks. It does not say your heart is healthy.

Fourteen days is still a sample. Some symptoms arrive monthly or less. For those patients, and for some people after a stroke with no clear cause, cardiologists turn to implantable loop recorders that sit just under the skin and watch for years.

Finding more is not always helping more. Long monitoring finds things, and some of what it finds is ambiguous. In mSToPS, monitoring brought more anticoagulant prescriptions and more cardiology visits; in GUARD-AF, most screen-detected atrial fibrillation lasted minutes, not hours. Anticoagulants prevent strokes and also cause bleeding. Whether an hour of atrial fibrillation across two weeks justifies a lifelong prescription is one of the live debates in cardiology, and a good clinician will weigh the burden of the arrhythmia, your stroke risk score, and your bleeding risk rather than reacting to a single word on the report.

A regulatory blemish worth knowing. In 2023 the FDA sent iRhythm a warning letter that raised concerns about its Zio AT telemetry device. The company responded with design and labeling changes that the agency cleared through two 510(k) submissions in 2024. The issue involved the telemetry product rather than the 14-day patch most people receive, but it belongs in any honest review.

Much of the evidence has a sponsor. Several of the strongest Zio studies include iRhythm scientists or pharmaceutical companies among the authors. That is normal for medical devices and does not invalidate the findings. Independent replication is still what the field should want, and what you should look for as new studies appear.

It is an adhesive worn for two weeks. Sensitive skin will let you know.

Zio Patch vs Holter Monitor vs Telemetry vs Smartwatch ECG

A Holter records several leads for a day or two; the Zio patch records one lead for up to two weeks; mobile telemetry adds live alerts for higher-risk patients; and a smartwatch or KardiaMobile captures on-demand strips you start yourself. The right choice depends on how often your symptoms occur and how quickly someone needs to know.

Feature	Zio patch (XT or Zio monitor)	Holter monitor	Mobile cardiac telemetry (MCOT, Zio AT)	Smartwatch or KardiaMobile ECG
Recording window	Up to 14 days, continuous	24 to 48 hours, continuous	Up to about 30 days, continuous	On demand, about 30 seconds per strip
Leads	Single lead	Multiple leads	Varies by device	One lead (watch); six leads (KardiaMobile 6L)
Real-time alerts	No	No	Yes	No; you start each recording
Prescription needed	Yes	Yes	Yes	No
Best for	Symptoms every few days to weeks	Daily symptoms	Patients who need fast action on a finding	Capturing a symptom in the moment; personal tracking

Consumer ECG devices and Zio are complements, not rivals. A watch notification or a strip from an AliveCor KardiaMobile 6L is often what sends someone to the cardiologist who then orders a Zio. Watches like the Apple Watch and rings like the Circular Ring 2 screen and catch moments; a two-week continuous recording settles the question. If you want to see where Zio sits among every clinical tool we cover, browse our clinical-grade device reviews.

How Much Does a Zio Patch Cost, and Does Insurance Cover It?

There is no shelf price, because you cannot buy a Zio patch. A clinician orders it, iRhythm bills your insurer, and what you pay depends on your deductible and coinsurance. Medicare claims data show Zio is routinely billed and reimbursed under Medicare, and iRhythm’s commercial-insurance analysis reflects broad use under private plans.

Practically, as of October 2026: ask for an estimate before the patch goes on. iRhythm and your insurer can tell you your expected share, and it is far easier to ask that question at the start than after a bill arrives. Because Zio is a prescribed diagnostic test, your out-of-pocket cost is generally a qualified medical expense for HSA and FSA purposes; confirm with your plan administrator. If cost is a real barrier and your symptoms happen most days, ask whether a shorter Holter would answer the same question. For daily symptoms, it often will.

Who Should Wear a Zio Patch, and Who Should Skip It?

The Zio patch suits people whose symptoms come and go on a scale of days to weeks and whose clinician needs to see the rhythm behind them. It is the wrong tool for emergencies, for symptoms that happen every day or only every few months, and for anyone looking for ongoing personal tracking.

Good candidates, in partnership with a clinician:

• Palpitations, a fluttering or pounding heartbeat, or “skipped beats” that arrive every few days or weeks.
• Unexplained lightheadedness or brief fainting spells where a rhythm cause is suspected.
• Suspected atrial fibrillation, including after an abnormal smartwatch or KardiaMobile reading.
• Checking how much atrial fibrillation remains after treatment, when your cardiologist wants a measured burden rather than a guess.

Better served by something else:

• Chest pain or pressure, fainting with injury, or a racing heart with shortness of breath. That is an emergency: call 911, and do not wait for a patch.
• Symptoms that happen every day: a 24 to 48 hour Holter is often enough.
• Symptoms that happen once every few months: an implantable loop recorder may be the better test.
• People who feel well and want to keep an eye on their heart: a consumer ECG device is the right category.

If you need a cardiologist or electrophysiologist to order and interpret monitoring, the Healthcare Discovery doctor directory lists clinicians by state and specialty.

What This Means for You

Atrial fibrillation is one of the quieter ways the Silent Assassin, cardiovascular disease, does its work. Blood lingers in a quivering upper chamber, a clot forms, and the first symptom can be a stroke. That is why a test that finds intermittent arrhythmias matters, and why it belongs in the larger story we tell in the Four Villains of Health and Longevity.

But the patch is the measurement, not the medicine. Much of the risk that turns a heart’s rhythm unstable is shaped by the Five Pillars. High blood pressure, excess weight, heavy drinking, and untreated sleep apnea all raise the odds of atrial fibrillation, which makes Sleep and Nutrition cardiac interventions as much as lifestyle ones. If you snore heavily or wake unrefreshed, a home sleep test such as WatchPAT One may be as relevant to your rhythm as any heart monitor. Movement, in the form of regular moderate exercise, builds the cardiovascular reserve that protects against every villain on the list, and our overview of what the evidence actually shows about heart health lays out where to start.

Then there is Mindset. Palpitations are frightening, and uncertainty can be worse than a diagnosis. One of the most underrated outcomes of a Zio test is the report that says your scary flutter happened during a perfectly normal rhythm. Holter’s ninety-pound backpack and today’s patch were built for the same purpose: to replace a guess with an answer. Two weeks of data will not make you healthier on its own. It will tell you, with more confidence than any test before it, what you are actually dealing with.

Frequently Asked Questions

Sources

1. Makarov LM. To the centennial of Norman Holter (1914 to 1983). Kardiologiia, 2015. PubMed
2. Barrett PM, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. American Journal of Medicine, 2014. DOI
3. Steinhubl SR, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA, 2018. DOI
4. Hannun AY, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nature Medicine, 2019. DOI
5. Gadaleta M, et al. Prediction of atrial fibrillation from at-home single-lead ECG signals without arrhythmias. npj Digital Medicine, 2023. DOI
6. Reynolds MR, et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries (CAMELOT). American Heart Journal, 2024. DOI
7. Singer DE, et al. Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. American Heart Journal, 2022. DOI
8. Singer DE, et al. Atrial fibrillation burden on a 14-day ECG monitor: findings from the GUARD-AF trial screening arm. JACC: Clinical Electrophysiology, 2025. DOI
9. Effect of screening for undiagnosed atrial fibrillation on stroke prevention (GUARD-AF primary results). Journal of the American College of Cardiology, 2024. DOI
10. iRhythm Technologies. AVALON real-world evidence builds on CAMELOT study (company announcement), 2025. iRhythm investor relations
11. iRhythm Technologies. FDA 510(k) clearance for design modifications to the Zio AT device (company announcement), October 30, 2024. iRhythm investor relations
12. U.S. Food and Drug Administration. 510(k) premarket notification K243650, Zio monitor, cleared August 15, 2025. FDA database